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Ekybion is a drug complex of 16 natural extracts and inorganic compounds designed to treat a variety of respiratory pathogens
of bacterial and viral origin. It is licensed throughout Europe for the treatment of respiratory tract infections from equine
parainﬂuenza type 3 and equine herpes virus type 1 in equine stables. The purpose of this paper was to test the eﬃcacy of Ekybion
on a well-developed animal model of inﬂuenza A infection and determine a mode of action. Experiments were performed with
Balb/c mice infected with a lethal dose of inﬂuenza A/PR/8/34 H1N1 virus and treated with nebulized Ekybion every 8h in a
time-dependant or dose-dependant fashion. These experiments showed that mice treated prior to infection with Ekybion had a
higher survival rates (∼46%) compared with untreated animals (∼0%). Paradoxically, these mice showed no signiﬁcant diﬀerence
in lung virus titer or weight loss. There was, however, a decrease in the level of GM-CSF, IL-6, and G-CSF cytokines in the lungs
of Ekybion-treated, infected mice. It is possible that decreases in proinﬂammatory cytokines may have contributed to increased
survivorship in Ekybion-treated inﬂuenza-infected mice.
1.Introduction
Inﬂuenza A virus is an enveloped, single stranded, negative
sense,segmentedRNAvirusbelongingtotheOrthomyxoviri-
dae family. Inﬂuenza A infection is of particular concern to
the human and veterinary medical communities. Seasonal
outbreaks in humans result in hundreds of thousands
of deaths annually; many are due to secondary bacterial
infections [1]. In addition, there are frequent outbreaks
of equine and canine inﬂuenza, especially among racing
animalshousedinlargegroups,whichfacilitatesspreadingof
the infection [2, 3]. Further concerns are raised by the ability
of inﬂuenza A viruses to undergo genetic reassortments
potentially creating new variant virus with zoonotic conse-
quences such as the ongoing transmission of avian inﬂuenza
strains to humans [4–6] and equine strains to dogs [7]. Most
recently, the global pandemic of swine origin inﬂuenza A
H1N1 has resulted in millions of conﬁrmed infections and
∼17,000 thousand conﬁrmed fatal cases [8].
Each year, seasonal inﬂuenza epidemics kill approxi-
mately 36,000 people in the USA and 250,000–500,000
people worldwide [9]. However, this is a complicated disease
where not just viral titers but the inﬂammatory reactions
are a major cause of morbidity and mortality [10–12]. The
systemicandbrochealveolarproductionofproinﬂammatory
cytokines is a well-established feature of inﬂuenza A infec-
tions with signiﬁcantly increased levels of TNF-α,I L - 1 β,I L -
6, IL-8, IL-10, RANTES, MCP-1, IFN-α,a n dI F N - γ in the
nasopharyngeal ﬂuids and plasma of patients [13–19]. Most
of the strategies explored to date for controlling or treating
inﬂuenza have focused on controlling the spread of the
infection and the use of vaccines or antiviral agents, rather
than combining antiviral agents with treating the lung and
systemicinﬂammatory reactionsthatoccurduring infection.2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: In vitro eﬃcacy of Ekybion. Inhibition of inﬂuenza A in MDCK cells was performed by treating cells infected with 0.01 MOI
inﬂuenza A/PR/8/43 H1N1 begnining at the indicated times pre- or postinfection and measuring virus titer by hemagglutination assay at
either 24 (grey bars) or 48 (black bars) hours postinfection. (n = 4, ∗∗P<. 001 by Two-Way ANOVA with Bonferroni posttests on Log2
transformed data).
Many natural compounds have been studied for their
potential immunomodulatory and antiviral eﬀects [20–
22]. Natural compounds have been widely accepted and
u s e df o rc e n t u r i e sa n dc o n t i n u et ob eu s e d ,e s p e c i a l l yi n
developing countries, where access to allopathic medicine is
limited due to availability and cost. However, clinical and
preclinical testing of alternative medicines to scrutinize their
purported uses is needed to validated alternative therapies
just as it is needed to validate allopathic medicine [23].
The presence of ﬂavonoids, ﬂavones, and other polyphenolic
compounds in many natural remedies often endows them
with their observed therapeutic beneﬁts [24]. Many natural
compounds have been examined for their antiviral or anti-
inﬂammatory eﬀects during inﬂuenza A virus infection, and
the active components in many cases have been isolated.
Some of these include the traditional Chinese medicines
Evodia rutaecarpa [25]a n dSophora ﬂavescens [26], as well
as several plants commonly used in Nepalese traditional
medicine [27].
In our paper we have examined the eﬀects of Eky-
bion, a drug complex developed to treat infections and
inﬂammation of the respiratory tract of horses caused by
a wide variety of infectious agents. Ekybion is a mixture
of 16 inorganic compounds and plant extracts commonly
used in European Pharmacopea [28, 29] and has been used
throughout Europe for nearly two decades for the treatment
of equines with various viral infections including equine
herpes virus type 1 and equine parainﬂuenza virus type 3
[30]. Previous research performed at the Pasteur Institute of
ParisshowedthatEkybioniscapableofinhibitingthegrowth
of several viruses in vitro including equine herpes virus type
1 (rhinopneumonitis), reovirus, rhinovirus, equine arteritis
virus (Bucyrus strain), and human parainﬂuenza virus type
3 (A. Jacquet, Pasteur Institute, personal communication).
However, Ekybion has yet to be tested in a controlled labo-
ratory setting against inﬂuenza A virus nor has it undergone
clinical evaluation for eﬃcacy in human diseases. We show
here that when used appropriately, Ekybion reduces mortal-
ity in mice infected with inﬂuenza A/PR/8/34 H1N1 virus.
2.MaterialsandMethods
2.1. Virus and Cells. Madin-Darby canine kidney (MDCK)
cells were maintained at 37
◦Cw i t h5 %C O 2 in MDCK
growth medium consisting of minimum essential media
(MEM)(Hyclone, Logan, UT) supplemented with100U/mL
penicillin, 100μg/mL streptomycin (Gibco, Invitrogen,
Carlsbad,CA),and10%fetalbovineserum(FBS)(Hyclone).
Inﬂuenza A/PR/8/34 H1N1 was obtained from ATCC and
grown in MDCK cells in virus growth medium consisting
of MEM supplemented with 100U/mL penicillin, 100μg/mL
streptomycin, and 1.0μg/mL TPCK-treated Trypsin (Sigma-
Aldrich, St. Louis, MO). Virus was harvested 2 days postin-
fection and stored at −80
◦C for future use. Virus was titered
by standard plaque assay on MDCK cells (see Virus titer
determination).
2.2. Mice. All animal experiments were performed using 6–
8-week-oldfemaleBalb/cmice,eachweighingapproximately
15–18g (Simonsen Laboratories, Gilroy, CA). Mice were
allowed food and water ad libitum throughout the studies.
Allanimalexperimentswerecarriedoutunderbiosafetylevel
2 conditions with protocols approved by the Institutional
Animal Care and Use Committee of Oregon State University.
2.3. Preparation of Ekybion. Ekybion consists of 16 pure
inorganic compounds or plant extracts prepared individ-
ually in 45–95% ethanol. An example of one extraction
p r o c e d u r ei sg i v e na sf o l l o w s :w h o l eﬂ o w e r sf r o mA r n i c a
Montana were ground and extracted in 45% ethanol in
puriﬁed water. Extracts were then examined by thin-layer
chromatography on silica plates using chloroform:glacial
acetic acid:methanol:puriﬁed water in 15:8:3:2 ratios,
respectively, as the solvent. Chromatography plates were
allowed to run their length, dried, and then examined under
UV light at 365nm. Under these conditions, 4 blue bands
a n d1r e db a n da r ev i s i b l ea tr e l a t i v ed i s t a n c e so f3 5 ,4 5 ,
75, 95, and 98%, respectively. Following extraction, the 16
individual solutions are combined together with puriﬁedEvidence-Based Complementary and Alternative Medicine 3
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Figure 2: Toxicity of Ekybion in Balb/c mice. (a) Twenty uninfected 8-week old female Balb/c mice were treated with 1X Ekybion every 8
hours for 10 days. Toxicity was determined by changes in daily weight compared to twenty untreated control animals. (b) Two animals from
each group were euthanized on day 4 of treatment and lung tissue collected for histological examination for tissue damage or inﬂammation.
Histological examination revealed no inﬂammation in treated or untreated control animals. (c) Two mice per group were treated every 8
hours for three days with Ekybion at the indicated concentrations and weighed daily to determine toxicity. (∗∗P<. 01 by Two-Way ANOVA
with Bonferroni posttests).
water and sterile ﬁltered. To make the working stock (1X),
the concentrated stock complex is diluted 1:500 in puriﬁed
water containing 0.2% ethanol. The ﬁnal working stock
contains the 16 components in puriﬁed water with a total of
0.4% ethanol (see Table 1).
2.4. Eﬃcacy of Ekybion in Cell Culture. MDCK cells
were grown in 24-well plates until conﬂuent and then
infected with 1000 plaque forming units (PFU) of inﬂuenza
A/PR/8/34 H1N1 virus in 50μLa t3 7
◦Cf o r1h o u r
with periodic shaking. Infection medium was removed,
and 500μL of virus growth medium was added (MEM
supplemented with 0.5μg/mL amphotericin B, 100U/mL
penicillin, 100μg/mL streptomycin, and 1μg/mL TPCK-
treated trypsin). Quadruplicate wells were treated at 1h
preinfection or 1, 2, 4, or 12 hours postinfection by adding
25μL Ekybion to each well making a 1:20 dilution. Medium
was collected at 24 and 48 hours postinfection and virus
titer determined by hemagglutination assay (see virus titer
determination).4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀects of Ekybion on inﬂuenza A infection in Balb/c mice. Female Balb/c mice were infected with 5MLD50 inﬂuenza A/PR/8/34
H1N1 and treated every 8 hours for 10 days beginning at indicated times and doses. Mice were weighed daily (data not shown), and
monitored for survival for 16 days (a). On day 2 postinfection, 2–5 mice per group were euthanized for determination of virus titer in
lungs by plaque assay (b). There were no signiﬁcant diﬀerences in weight loss or lung pathology between any groups. However, there was
a dose-dependant antiviral response with signiﬁcant reduction in virus titer seen in the 10X group (P<. 05 by one-way ANOVA with
Dunnett’s posttest). Survival in the 1X 2min group was also signiﬁcantly improved (∗∗P<. 01 by log-rank (Mantel-Cox) test and Gehan-
Breslow-Wilcoxon test).
Table 1: Composition of Ekybion.
Plant
extracts
Arnica montana, Baptisia tinctoria, Bryonia alba,
Lytta vesicatoria, Echinacea angustifolia,
Phellandrium aquaticum, Pulsatilla nigricans, Sepia
oﬃcinalis,a n dThuja occidentalis
Inorganic
compounds
nitric Acid, phosphorus, calcium phosphate,
potassium bisulphate, calcium hydrate, calcium
sulﬁde, iodine, and silicic acid
2.5. Eﬃcacy of Ekybion In Vivo. Mice were infected with
1000PFU (approximately 5 mouse lethal dose 50 (5MLD50))
of inﬂuenza A/PR/8/34 H1N1 in 100μL PBS by intranasal
administration (IN) following anesthesia with 67mg/Kg
Ketamine and 4.5mg/Kg Xylazine. Ekybion was delivered
through inhalation to mice by means of a nebulizer (Inspi-
ration Nebulizer, Respironics New Jersey, Inc., Parsippany,
N J ) .A l lm i c ew e r et r e a t e dw i t hE k y b i o ne v e r y8h o u r sf o r
ten days by directly holding their nose over a stream of
nebulized Ekybion as indicated below. Two to ﬁve mice
in each group were euthanized by isoﬂurane followed by
cervical dislocation on day two postinfection for removal of
lung tissue for virus titration by plaque assay and histological
examination. In addition, mice were weighed daily for 16
days to determine illness and time to death or recovery.
Determination of dose response was carried out by
treating mice with diﬀerent concentrations (1X or 10X)
of nebulized Ekybion for the same duration of time, or
by treating with the same concentration for diﬀerent time
durations (2 or 4 minutes). All dose response groups began
treatmentat3hourspriortoinfectionandweretreatedevery
8 hours for 10 days. For time response experiments, mice
were treated with the same dose of Ekybion (1X) but starting
at diﬀerent time points before or after infection (3 hours
preinfectionand6hourspostinfection)andcontinuingevery
8h o u r sf o r1 0d a y s .
2.6. Toxicity of Ekybion. 20 mice were treated with 1X
Ekybion 3 times daily for 10 days. Mice were weighed daily
andmonitoredforillness.Onday4oftreatment,5micewere
euthanized and lung tissue collected for histopathological
examination (see Histopathological examination of lung
tissue). Additionally, groups of 2 mice each were treated with
various concentrations of Ekybion from 1X to 250X, or 0.4%
ethanolindiH2O(control),byholdingnosesofmicedirectly
over nebulized Ekybion for 2 minutes, every 8 hours, for
three days. All mice were weighed daily and monitored for
signs of illness.
2.7. Virus Titer Determination. To determine the titer of
virus from cell culture experiments hemagglutination assay
was performed by making twofold serial dilutions of the
collected medium in 50μL of phosphate buﬀered saline
(PBS) in round bottom 96-well plates. 50μLo f0 . 5 %c h i c k e n
redbloodcells(PMLMicrobiologicals,Portland,OR)inPBS
wasthenaddedtoeachwellandtheplatesincubatedatroom
temperaturefor1h. Virus titer wasdetermined as the highest
dilution in which duplicate wells showed greater than 50%
hemagglutination.
Virus titers in lung tissue homogenates were determined
as reported previously [31] by making ten-fold serial dilu-
tions and infecting monolayers of MDCK cells in duplicate
wells of 24-well plates. Titers were determined by the highest
dilution in which duplicate wells contained at least 5 plaques
per well. Plaque counts were then normalized based on lung
weights and all lung titers are presented as PFU/g lung.Evidence-Based Complementary and Alternative Medicine 5
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Figure 4: Immunomodulatory eﬀects of Ekybion. Lung tissue previously harvested at day 2 postinfection was homoginized and tested for
expression levels of 22 cytokines. Only those cytokines with signiﬁcant changes are shown. (a) Expression levels were determined initially by
membrane-based antibody array (RayBio) and normalized to uninfected untreated control animals. (b) Subsequent analysis was performed
by multiplex bead-based cytokine detection (Millipore), and expression levels are displayed as pg/g lung tissue. 2min = 1X treatment for
2min, 4min = 1X treatment for 4min, and 10X = 10X treatment for 2min (∗P<. 05 by Student’s t-test, n = 2-3 per group).
2.8. Histopathological Examination of Lung Tissue. Sec-
tions of lung tissue were ﬁxed in 4% neutral buﬀered
paraformaldehyde, embedded in paraﬃn and sectioned at
5 micron thickness via routine processing. Sections were
stained with hematoxylin and eosin. All sections were
evaluated by a veterinary pathologist (Kristin M. Patton).
Tissue changes were subjectively ranked according to degree
of inﬂammation, extent of inﬂammation, and degree of
necrosis (0 = no inﬂammation, 1 = mild inﬂammation, 2 =
moderate inﬂammation, and 3 = severe inﬂammation).
2.9. Cytokine Levels in Lungs. Cytokine levels in mouse lungs
were determined using RayBio Mouse Cytokine Antibody
ArrayI(RayBiotech,Norcross,GA),whichtestsfor22mouse
cytokines. Procedure was performed per manufacturer’s
instructionsusing500μLmouselunghomogenate(seeVirus
titer determination) diluted 1:2 in blocking buﬀer. Arrays
were imaged and analyzed on a ChemiDoc XLS using
Quantity One software (Bio-Rad, Hercules, CA). Additional
cytokine analysis was also performed using the mouse
cytokine 22-plex kit from Millipore (Billerica, MA) and ana-
lyzing on a Luminex 200 platform (Luminex Corporation,
Austin, TX) per manufacturer’s recommendations.
2.10. Statistics. All statistical analyses were performed using
GraphPad Prism version 4.00 for Windows (GraphPad
Software,SanDiego,CA).Two-wayANOVAwithBonferroni
posttest was used to determine signiﬁcance of in vivo toxicity
by weight loss. One-Way ANOVA with Dunnett’s posttest
was used to test for treatment eﬀect on virus titer and
histopath scores. Student’s t-test was used for cytokine
expression proﬁling, and log-rank (Mantel-Cox) test and6 Evidence-Based Complementary and Alternative Medicine
Table 2: Survivorship for Balb/c mice treated with Ekybion.
Treatment start Administration time
(Ekybion conc.)
Survivorship
live/total
Mean day of
death ± SD
Log rank test
3h o u rp r e 2min (control) 0/13 9.23 ±2.13
3h o u rp r e 2min (1X) 6/13 9.86 ±1.77 P = .0078
3h o u rp r e 4min (1X) 0/6 10.0 ±1.67
3h o u rp r e 2min (10X) 1/6 9.20 ±1.10
6 hour post 2min (1X) 0/7 9.43 ±2.37
Eight-week-old female Balb/c mice were infected with 5MLD50 of inﬂuenza A/PR/8/34 H1N1 and treated three times daily for 10 days.
Gehan-Breslow-Wilcoxon test were used for determining the
signiﬁcance of survivorship.
3. Results
3.1. In Vitro Eﬃcacy. Although Ekybion has been used
in Europe to treat respiratory diseases in equines, it has
never been empirically tested for its eﬃcacy on inﬂuenza
A in a controlled laboratory setting. Based on previous
researchwithEkybion(A.Jacquet,PasteurInstitute,personal
communication), we tested the ability of a 1:20 dilution
of the working stock of Ekybion in virus growth medium
to inhibit inﬂuenza A/PR/8/34 H1N1 strain in MDCK
cells. Treatment began at diﬀerent times before or after
infection (1h preinfection, or 1, 2, 4, or 12h postinfection).
Control cells were treated with a 1:20 dilution of ddH2O
containing 0.4% ethanol in virus growth medium. Samples
were taken at 24h and 48h postinfection, and inﬂuenza titer
was determined by hemagglutination assay. Pretreatment or
posttreatment of MDCK cells signiﬁcantly reduced virus
growth for at least 48h when treatment was initiated by 12
hours postinfection (Figure 1). Inhibition of inﬂuenza was
most prominent when treatment was performed prior to or
within 4 h after infection. These results indicate that Ekybion
is capable of signiﬁcantly reducing inﬂuenza A/PR/8/34
H1N1 virus growth in cell culture when treatment is started
within the ﬁrst 12h of infection.
3.2. Toxicity. Initially we tested the toxicity of 1X nebulized
Ekybion by treating one group of mice three times daily
for 10 days and comparing them to untreated controls. We
observed that 1X Ekybion treated mice did gain slightly
less weight than control animals (Figure 2(a)) but showed
no other eﬀects and had normal lung tissue compared
to controls (Figure 2(b)).We next tested various doses of
Ekybion ranging from 1X to 250X and treated mice for
three days with nebulized Ekybion. No toxicity was observed
until a concentration of 50X, and signiﬁcant toxicity was
not observed until 250X, resulting in a 16% decrease in
body weight (Figure 2(c)). Together, these results indicate
that there was no toxicity associated with Ekybion at the
concentration intended for clinical use (1X).
3.3. In Vivo Eﬃcacy. Next, we evaluated the eﬃcacy of
Ekybion at inhibiting inﬂuenza virus in infected mice. Doses
were administered by either increasing the time of the
treatment (2min versus 4min) or by keeping the time
constant (2min) and increasing the concentration of the
Ekybion used in the nebulizer (1X versus 10X). Groups
of mice were infected with 5MLD50 inﬂuenza A/PR/8/34
H1N1 and treated with various concentrations of Ekybion
beginning at 3h preinfection and continuing every 8h
for ten days in all groups. The control group was treated
with 0.4% ethanol in ddH2O. Additionally, one group was
treated with 1X Ekybion for 2min each starting at 6h after
infection. Mice were weighed daily for 16 days and 2–5
mice were sacriﬁced on day 2 postinfection to determine the
virus titer in lung tissue. We saw no signiﬁcant diﬀerences
in weight loss (data not shown). We also observed that
treatment with 1X Ekybion for 2min (the lowest dose) was
the most eﬀective with a 46% survivor rate compared to 0%
in the control treatment group (Table 2 and Figure 3(a)).
However, treatment with higher doses (10X) or treatment
for longer periods of time (4min) had no beneﬁcial eﬀect
on survival. We did observe a dose response eﬀect on virus
titer with the 10X 2min treatment group having a signiﬁcant
decrease in virus titer of 0.53Log10 (Figure 3(b)). In all,
our results indicate that the intended 1X dose of Ekybion
used in a prophylactic manner may reduce mortality in mice
inoculated with a lethal dose of inﬂuenza A/PR/8/34 H1N1
but not by reducing virus titers.
3.4. Immunomodulation. Lung tissue homogenates collected
at 2 days postinfection were utilized to determine the
cytokine levels at the site of infection. Mice treated with
Ekybion displayed a general trend toward lower cytokine
production with signiﬁcant decreases in GCSF (6.0-fold
decrease), GM-CSF (4.0-fold decrease), and IL-6 (3.5-fold
decrease) in the 1X 2min treatment group (Figure 4(a)).
Further decreases were generally seen in the 1X 4min
group or the 10X 2min group with additional signiﬁcant
decreasesinIFN-γ andMIP-1α(Figure 4(b)).Basedonthese
lung cytokine levels, it appears that Ekybion may modulate
the immune response to inﬂuenza A infections in vivo in
addition to having a direct antiviral eﬀect. It is possible that
higher concentrations (10X) of Ekybion may have proved
ineﬀective due to excessive immunosuppression which may
have negated any beneﬁt from reduced virus growth.
4. Discussion
Ekybion was speciﬁcally designed to provide treatment
which is eﬀective on a wide variety of infections of diﬀerentEvidence-Based Complementary and Alternative Medicine 7
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Figure 5: Theoretical mechanism of action and method for improved eﬃcacy. (a) The current composition of Ekybion contains plant
extracts known to have antiviral and immunomodulatory potential. The beneﬁcial and negative interplay between these two eﬀects is shown
here where mild inhibition of inﬂammation (resulting in relief of some symptoms associated with inﬂuenza infection) is beneﬁcial but
overt inhibition of inﬂammation (impaired tissue repair or viral clearance late in infection) is detrimentla to disease resolution. Conversely,
increasing inhibition of virus replication is beneﬁcial. (b) In order to maximize the therapeutic beneﬁt obtained from Ekybion we propose
optimizing the concentrations of the 16 components to increase the antiviral properties and limit the immunomodulatory eﬀects.
origins by combining a number of plant extracts and inor-
ganic compounds suspected to possess antimicrobial and/or
immunomodulatory properties. Echinacea angustifolia has
been shown to be the most potent Echinacea species with
respect to immune modulation [32, 33]. Recent studies
show that Echinacea has both anti-inﬂammatory and anti-
inﬂuenza eﬀects [10]. Arnica montana has also been shown
to possess anti-inﬂammatory and antimicrobial properties
mediated by the presence of two compounds, namely thymol
and helenalin [34, 35]. Thymol is capable of inhibiting
elastase release from activated neutrophils, possibly reducing
some of the collateral damage associated with inﬂammation
[36] and inhibiting inﬂuenza A replication due to nonspe-
ciﬁc inhibition of protein synthesis [37]. Helenalin’s anti-
inﬂammatory properties are mediated through inhibition
of NF-κB signaling by alkylating the p65 subunit [38].
Though not speciﬁcally demonstrated for helenalin, it has
been shown that inhibition of NF-κB results in inhibition
of inﬂuenza due to a decrease in caspase 3 activity, which is
necessary for the nuclear export of viral ribonucleoprotein
complexes [39–41]. Finally, Thuja occidentalis extracts have
been extensively studied alone or in combination with other
plantsfortheirantimicrobialandimmunomodulatoryprop-
erties, and a review was recently published in this journal
[42]. In all, there are several components present in Ekybion
that have known antimicrobial and immunomodulatory
properties which would be beneﬁcial for the resolution of
inﬂammation and infections.
We have shown here that Ekybion treatment of mice
infected with inﬂuenza A/PR/8/34 H1N1 results in an
increase in survivorship of 46% over control groups if
administered at the intended 1X concentration and in
a prophylactic manner. In this model, inﬂuenza-infected
mice treated with Ekybion showed signiﬁcant decreases in
GCSF, GM-CSF, and IL-6 (Figure 4(a)). Further signiﬁcant
decreases were also seen in the 1X 4min or the 10X
2min groups with IFN-γ and MIP-1α (Figure 4(b)). In
addition, we observed a dose dependant decrease in viral
titers in vivo (Figure 3(b))a n din vitro (Figure 1). These
results indicate that Ekybion possesses both antiviral and
immunomodulatorypropertiesduringinﬂuenzaAinfection.
Based on our observations, we propose the follow-
ing mechanism by which Ekybion improves survivorship
(Figure 5(a)). For the 1X treatment group, although we
observed no reduction in virus titer in vivo at this dose,
we did observe a mild anti-inﬂammatory eﬀect which may
have provided some relief of symptoms associated with
an inﬂuenza infection. This observation is similar to the
results obtained for a natural compound, Glycyrrhizin, in
the treatment of inﬂuenza infection. Glycyrrhizin, which
is present in liquorices roots and used in a number of
traditional cough remedies, reduces the severity of infection
in mice infected with inﬂuenza A H2N2 and reduced the
lethality of the infection but did not aﬀect virus replication
[43].In thecaseofhigher doses ofEkybion (10X for2min or
1X for 4min), there was a beneﬁcial decrease in virus load,
but any beneﬁt was overshadowed by excessively impaired
inﬂammation (Figure 5(a)), especially with respect to the
important antiviral cytokine IFN-γ which has been shown to
aﬀect survival of mice infected with inﬂuenza A, but without
aﬀecting viral titers [44]. Instead, IFN-γ has been shown to
play a critical role in shaping the production and inﬁltration
of NK cells early in infection and T-cell inﬁltration later
in inﬂuenza infection, thus reducing the amount of tissue
damage while still leading to proper viral clearance [44]. We
therefore hypothesize that at higher doses of Ekybion, mice
died due to an unbalanced immune response which resulted
in either increased tissue damage or impaired viral clearance
later in infection than examined in this paper. Furthermore,
the 1X 4min treatment group exhibited additional signs of
stress from extended restraint during treatment thus adding
to the mortality seen in this group. These ﬁndings bring8 Evidence-Based Complementary and Alternative Medicine
into stark relief the delicate balancing act of modulating
immune responses during an infection. Future research with
Ekybionwillgreatlybeneﬁtfromexaminingtheantiviraland
anti-inﬂammatory eﬀects of the 16 compounds separately
and then determining the concentration of each compound
whichwillprovidemaximumbeneﬁtforvirusinhibitionand
modulation of inﬂammation (Figure 5(b)).
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